Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases.

about

Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases.

Item

http://www.wikidata.org/entity/Q47198384

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Long-term safety of rituximab ...... oimmune neurological diseases.

@en

Long-term safety of rituximab ...... oimmune neurological diseases.

@nl

type

Item

label

Long-term safety of rituximab ...... oimmune neurological diseases.

@en

Long-term safety of rituximab ...... oimmune neurological diseases.

@nl

prefLabel

Long-term safety of rituximab ...... oimmune neurological diseases.

@en

Long-term safety of rituximab ...... oimmune neurological diseases.

@nl

P1476

Long-term safety of rituximab ...... oimmune neurological diseases.

@en

P2093

Adil Javed

http://www.w3.org/2001/XMLSchema#string

Alexandros Tselis

http://www.w3.org/2001/XMLSchema#string

Christina Caon

http://www.w3.org/2001/XMLSchema#string

Evanthia Bernitsas

http://www.w3.org/2001/XMLSchema#string

Fen Bao

http://www.w3.org/2001/XMLSchema#string

Jessica Chorostecki

http://www.w3.org/2001/XMLSchema#string

Navid Seraji-Bozorgzad

http://www.w3.org/2001/XMLSchema#string

Omar Khan

http://www.w3.org/2001/XMLSchema#string

Shitiz Srivastawa

http://www.w3.org/2001/XMLSchema#string

P2860

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.

Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.

From the bench to the bedside: ways to improve rituximab efficacy.

Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis

A unique cell surface antigen identifying lymphoid malignancies of B cell origin.

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients.

Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?

P304

e0190425

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0190425

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Anza B Memon

P577

2018-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29309416

http://www.w3.org/2001/XMLSchema#string

P932

5757948

http://www.w3.org/2001/XMLSchema#string